Apollo Therapeutics Closes $226.5 Million Series C Financing
September 15, 2023
Apollo is a part of a research and development platform for the development of new medicines, with program selection being hesitant to indication and primarily driven by quality of science or the potential to transform the standard of care in major commercial markets, according to the press release.